Glooko Releases New Version of Mobile App, Presents Usability Outcomes From Mobile Insulin Dosing System (MIDS) Study | Financial Buzz

Glooko Releases New Version of Mobile App, Presents Usability Outcomes From Mobile Insulin Dosing System (MIDS) Study

Glooko,
the leader in diabetes data management, today announced participation in
the 78th Annual American Diabetes Association (ADA) meeting taking place
this weekend in Orlando, Fla. At the event, Glooko will demonstrate the
new version 5.0 of its diabetes management mobile application and will
share results from a recent human factors study on its Mobile Insulin
Dosing System (MIDS) for long-acting insulin (LAI) titration, which was FDA
cleared earlier this year.

With over 95% of glucose, insulin pump and exercise devices supported,
the new Glooko Mobile App focuses on features that add context to
glucose and insulin data. Version 5.0 makes tracking personal lifestyle
events like exercise, food and medication easier and faster. The new
release includes:

“Glooko’s universal platform for diabetes data management not only
seamlessly captures data from most diabetes devices in the market, but
now makes lifestyle tracking easier than ever before,” said Dave Conn,
Chief Commercial Officer at Glooko. He continued, “Adding further
insights like food, medication, insulin, exercise and notes about mood,
feelings and behaviors provides relevant context to an individual’s
glucose readings and helps people with diabetes and clinicians better
augment self-care and the overall clinical care plan.”

In addition to demonstrating the new Glooko Mobile App and the recently
released version of the Glooko
Web App, Glooko will also be presenting a poster at the ADA
conference on Saturday, June 23, from 11:30-12:30 pm. The poster covers
the results from a recent human factors study on the MIDS application –
proving that MIDS is simple, effective, and easy-to-use for people with
type 2 diabetes of varying ages, LAI experience, and smartphone use
without training or reading a user manual. Participants reported
overwhelmingly positive feedback and no participant expressed
frustration when completing tasks despite any lack of training or prior
experience with digital diabetes tools.

To learn more visit us in booth #1137 on the exhibition floor or come
see our poster in the General Poster Session, Category 12-C Clinical
Therapeutics/New Technology- Insulins #1055-P.

About Glooko

Glooko provides insights that improve outcomes for people with diabetes
(PWDs) and their care teams. Glooko syncs data from the world’s most
popular diabetes devices and major fitness and activity trackers and
supplies personalized, timely insights based on blood glucose, food,
insulin, blood pressure, diet and weight data. Trusted by the world’s
leaders in diabetes care, Glooko is used by 7,000 clinics and over 1.5
million PWDs in 23 countries across 15 languages. Learn more by visiting www.glooko.com

©2018 Glooko, Inc. Glooko and Diasend are trademarks of Glooko, Inc. All
rights reserved. PRM 0504 Rev A

View source version on businesswire.com: https://www.businesswire.com/news/home/20180622005075/en/